InSysBio announces its participation in JuliaCon Global 2026 (Conference on the Julia programming language) which is to be held from August 10-15, 2026 at Johannes Gutenberg University Mainz, Germany. Ivan Borisov, Senior Software Developer, InSysBio, and Evgeny Metelkin, Technology Director, InSysBio, will give a talk:
August 12, 12:00–12:15 (Europe/Berlin), Room 4:
Ivan comments on the talk, "Virtual Populations (VPops) are widely used in Quantitative Systems Pharmacology (QSP) to represent variability in patient responses to therapy using parameterized dynamical models. Unlike traditional modeling approaches that focus on average treatment effects, VPop methods aim to reproduce the full distribution of clinical outcomes observed in trials.
We introduce VPopMIP, a Julia package implementing a Mixed-Integer Programming (MIP) formulation for generating VPops that match clinical endpoints. In contrast to many existing approaches that require individual-level patient data, VPopMIP enables calibration to published clinical summary statistics (e.g., response rates, medians, and confidence intervals), which are more commonly available in practice.
The method formulates virtual patient selection as a constrained optimization problem that enforces agreement with multiple outcome measures across therapies.
We demonstrate the methodology using a solid tumor model with multiple efficacy endpoints across treatment regimens. The results illustrate how MIP-based selection provides an efficient way to construct clinically consistent virtual populations".
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | June 2025 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
|
3
1.
03 Jun 2025 20:43
InSysBio to present Integration of Cytocon DB and fIVE DB with Heta for QSP modeling
InSysBio releases an integration of CYTOCON DB and fIVE DB with Heta. Now Heta format is upgraded to allow direct query to databases from the QSP model code without working with database websites.
|
4
|
5
|
6
|
7
|
8
|
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
1.
18 Jun 2025 18:30
InSysBio to publish the new article in CPT: Pharmacometrics & Systems Pharmacology
The new article “Quantitative Systems Pharmacology Model That Describes Neurofilament Light Dynamics During Alzheimer's Disease Progression” by Polina Maliukova, Tatiana Karelina was published in CPT: Pharmacometrics & Systems Pharmacology Journal on June 17, 2025
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
1.
25 Jun 2025 14:32
The project aims at translational mechanistic modeling of antibodies to predict human pharmacokinetics and target occupancy in cerebrospinal fluid
InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the extension of collaboration with discoveric bio alpha, a biotechnology company taking next generation antibody technologies into Alzheimer’s Disease.
|
26
|
27
|
28
|
29
|
|
30
| ||||||
Thank you for your message! We will get back to you shortly.
